AstraZeneca invests $2 billion for stake in Summit Therapeutics to back its cancer drug

AstraZeneca announced on Monday that it will invest $2 billion to acquire a minority equity stake in Summit Therapeutics. The investment gives AstraZeneca a slice of the biotech as the companies move forward with a partnership focused on Summit’s cancer drug candidate.

The deal, long speculated by industry observers, marks AstraZeneca’s continued effort to strengthen its oncology pipeline through strategic collaborations. By taking an equity position, AstraZeneca aims to share in the development risk and potential upside of the drug.

Summit Therapeutics will retain its independence while benefiting from AstraZeneca’s resources and expertise, positioning both firms to advance the cancer therapy toward later stage trials and eventual market launch.